Showing results (81-90 of 105) with videos related to
Sort By:
Pageof 11
Pharmacogenetics|June 1, 1995
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjectsM L Dahl, Q Y Yue, H K Roh, et al.Pharmacogenetics|December 1, 1992
Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancerM Ingelman-Sundberg, I Johansson, I Persson, et al.British Journal of Clinical Pharmacology|November 1, 1995
Patterns of drug treatment of schizophrenic patients in Estonia, Spain and SwedenR A Kiivet, A Llerena, M L Dahl, et al.Clinical Pharmacology and Therapeutics|April 1, 1996
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixolM Jerling, M L Dahl, A Aberg-Wistedt, et al.Clinical Pharmacology and Therapeutics|November 3, 1998
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypesQ Y Yue, Z H Zhong, G Tybring, et al.EXS|January 1, 1994
Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicityM Ingelman-Sundberg, I Johansson, I Persson, et al.Pharmacogenetics|December 12, 2001
Functional polymorphism in the alcohol dehydrogenase 3 (ADH3) promoterJ J Hedberg, M Backlund, P Strömberg, et al.The Journal of International Medical Research|January 1, 1997
Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patientsE K Syvälahti, T Taiminen, S Saarijärvi, et al.European Journal of Clinical Pharmacology|January 1, 1993
Polymorphic 2-hydroxylation of desipramine. A population and family studyM L Dahl, L Iselius, C Alm, et al.Pharmacogenetics|April 1, 1993
Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypesL Bertilsson, C O Meese, Q Y Yue, et al.Pageof 11